Athira Pharma (NASDAQ:ATHA) Posts Quarterly Earnings Results, Misses Expectations By $1.51 EPS

Athira Pharma (NASDAQ:ATHA) posted its quarterly earnings data on Thursday. The company reported ($1.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($1.51), Zacks reports.

Athira Pharma Stock Down 4.0%

Shares of NASDAQ:ATHA traded down $0.16 during trading on Friday, hitting $3.85. The stock had a trading volume of 43,504 shares, compared to its average volume of 27,304. Athira Pharma has a 12-month low of $2.20 and a 12-month high of $8.26. The stock has a market capitalization of $15.17 million, a price-to-earnings ratio of -0.40 and a beta of 3.04. The stock has a 50-day simple moving average of $3.96 and a two-hundred day simple moving average of $3.59.

Analyst Ratings Changes

A number of research firms have commented on ATHA. Mizuho set a $4.00 price target on Athira Pharma in a research note on Friday, September 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Athira Pharma in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Athira Pharma presently has a consensus rating of “Sell” and a consensus target price of $4.00.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.